Compare NFE & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | ANGO |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 462.0M |
| IPO Year | 2018 | 2004 |
| Metric | NFE | ANGO |
|---|---|---|
| Price | $1.06 | $10.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $7.70 | ★ $19.33 |
| AVG Volume (30 Days) | ★ 5.5M | 315.9K |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.92 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,364,860,000.00 | $291,010,000.00 |
| Revenue This Year | N/A | $9.11 |
| Revenue Next Year | $79.17 | $4.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.17 |
| 52 Week Low | $0.98 | $8.27 |
| 52 Week High | $12.59 | $13.99 |
| Indicator | NFE | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 47.80 |
| Support Level | $1.03 | $10.37 |
| Resistance Level | $1.40 | $11.03 |
| Average True Range (ATR) | 0.09 | 0.34 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 2.86 | 40.24 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.